Mind Medicine (MindMed) Inc MNMD

Alternate Symbol(s): N.MMED.WS | N.MMED.WA | N.MMED.WR | N.MMED

Healthcare Psychedelics

Mind Medicine (MindMed) Inc. is a clinical-stage biopharmaceutical company, which is engaged in developing products to treat brain health disorders. It is developing a pipeline of product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM-120 and MM-402, the Company's product candidates. MM120, is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that it is developing for the treatment of generalized anxiety disorder (GAD). MM-120 is also being studied in a subperceptual repeat administration dosing regimen for the treatment of attention deficit hyperactivity disorder (ADHD). MM-402, also referred to as R(-)-MDMA, is the Company's form of the R-enantiomer of 3,4-methylenedioxymethampheta (MDMA), which the Company is developing for the treatment of autism spectrum disorder (ASD).

NDAQ:MNMD - Post by User

Mind Medicine (MindMed) Inc

<< Previous

Bullboard Posts

Next >>

Post by Streetbrainon Jan 11, 2021 8:52am

224 Views

Post# 32265647

Neurotech Pioneer Kernel Partnees with Psychedelic company

Looks like MMED AND CYBN are pulling away from the pack later !!!

https://www.businesswire.com/news/home/20210111005430/en/Cybin-Partners-with-Kernel-to-Leverage-its-Breakthrough-Neuroimaging-Technology-for-Psychedelic-Therapeutics

https://www.cybin.com/kernel/

<< Previous

Bullboard Posts

Next >>

Global Tungsten Market and Supply Security